The company faces securities fraud investigation following disclosure of executive retention bonuses. The stock experienced a sharp 21.45% decline, indicating significant investor concern about potential misconduct and the appropriateness of executive compensation during what may be a challenging period for the company.
Conducted the pivotal Phase 3 SENTRY trial in collaboration with Menarini. Positive results demonstrating selinexor's efficacy in combination therapy could support regulatory approval and market expansion for the XPO1 inhibitor in myelofibrosis.
Articles that tag KPTI but are mainly about other companies.
Karyopharm's selinexor is in Phase III development with XPO1 inhibition mechanism, representing a late-stage asset in the advanced endometrial cancer pipeline.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
